Belimumab

Last Updated: 02/24/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1302 publications

Recent advances in immunosuppressive therapy for lupus nephritis.

Recent advances in immunosuppressive therapy for lupus nephritis.

Journal: Immunological medicine

Published: January 07, 2026

Epidemiological perspectives on SLE and APS in MENA: Burden, barriers, and a path toward improved outcomes.

Epidemiological perspectives on SLE and APS in MENA: Burden, barriers, and a path toward improved outcomes.

Journal: Lupus

Published: December 19, 2025

Belimumab versus calcineurin inhibitors for cancer risk in lupus nephritis.

Belimumab versus calcineurin inhibitors for cancer risk in lupus nephritis.

Journal: Rheumatology (Oxford, England)

Published: December 18, 2025

B-cell activating factor plays a critical role in CAR-T cell-associated cytokine release syndrome.

B-cell activating factor plays a critical role in CAR-T cell-associated cytokine release syndrome.

Journal: bioRxiv : the preprint server for biology

Published: December 17, 2025

Effectiveness of Rituximab, Belimumab, and Thrombopoietin Receptor Agonists in Refractory Immune Thrombocytopenia Associated With Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis.

Effectiveness of Rituximab, Belimumab, and Thrombopoietin Receptor Agonists in Refractory Immune Thrombocytopenia Associated With Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis.

Journal: Cureus

Published: December 14, 2025

Lessons Learnt from the Belimumab Trials in Systemic Lupus Erythematosus.

Lessons Learnt from the Belimumab Trials in Systemic Lupus Erythematosus.

Journal: International journal of molecular sciences

Published: November 25, 2025

Efficacy of adding belimumab to hydroxychloroquine for patients with serologically active clinically quiescent in systemic lupus erythematosus: A retrospective study.

Efficacy of adding belimumab to hydroxychloroquine for patients with serologically active clinically quiescent in systemic lupus erythematosus: A retrospective study.

Journal: Lupus

Published: November 24, 2025

Concurrent Use of Anifrolumab and Belimumab in a Patient With Systemic Lupus Erythematosus Presenting With Recurrent Severe Cutaneous Involvement and Lupus Nephritis.

Concurrent Use of Anifrolumab and Belimumab in a Patient With Systemic Lupus Erythematosus Presenting With Recurrent Severe Cutaneous Involvement and Lupus Nephritis.

Journal: Cureus

Published: November 19, 2025

Biological targeted therapy for lupus nephritis-the role of BLYS and APRIL.

Biological targeted therapy for lupus nephritis-the role of BLYS and APRIL.

Journal: Renal failure

Published: November 17, 2025

Correction to: Unsupervised machine learning identifies distinct SLE patient endotypes with differential response to belimumab.

Correction to: Unsupervised machine learning identifies distinct SLE patient endotypes with differential response to belimumab.

Journal: Rheumatology (Oxford, England)

Published: November 14, 2025

Preventing relapse of cerebral infarction with belimumab in a patient with primary anti-phospholipid syndrome: a case report.

Preventing relapse of cerebral infarction with belimumab in a patient with primary anti-phospholipid syndrome: a case report.

Journal: Scandinavian journal of rheumatology

Published: November 04, 2025

Safety and tolerability of combination rituximab and belimumab therapy in systemic lupus erythematosus: A systematic review.

Safety and tolerability of combination rituximab and belimumab therapy in systemic lupus erythematosus: A systematic review.

Journal: Lupus

Published: October 30, 2025

Showing 1-12 of 1,302

Last Updated: 02/24/2026